The strong anti-kinetoplastid properties of bee propolis : composition and identification of the active agents and their biochemical targets
Ebiloma, Godwin U. and Ichoron, Nahandoo and Siheri, Weam and Watson, David G. and Igoli, John O. and De Koning, Harry P. (2020) The strong anti-kinetoplastid properties of bee propolis : composition and identification of the active agents and their biochemical targets. Molecules (Basel, Switzerland), 25 (21). 5155. ISSN 1420-3049 (https://doi.org/10.3390/molecules25215155)
Preview |
Text.
Filename: Ebiloma_etal_Molecules_2020_The_strong_anti_kinetoplastid_properties_of_bee_propolis.pdf
Final Published Version License: Download (16MB)| Preview |
Abstract
The kinetoplastids are protozoa characterized by the presence of a distinctive organelle, called the kinetoplast, which contains a large amount of DNA (kinetoplast DNA (kDNA)) inside their single mitochondrion. Kinetoplastids of medical and veterinary importance include Trypanosoma spp. (the causative agents of human and animal African Trypanosomiasis and of Chagas disease) and Leishmania spp. (the causative agents of the various forms of leishmaniasis). These neglected diseases affect millions of people across the globe, but drug treatment is hampered by the challenges of toxicity and drug resistance, among others. Propolis (a natural product made by bees) and compounds isolated from it are now being investigated as novel treatments of kinetoplastid infections. The anti-kinetoplastid efficacy of propolis is probably a consequence of its reported activity against kinetoplastid parasites of bees. This article presents a review of the reported anti-kinetoplastid potential of propolis, highlighting its anti-kinetoplastid activity in vitro and in vivo regardless of geographical origin. The mode of action of propolis depends on the organism it is acting on and includes growth inhibition, immunomodulation, macrophage activation, perturbation of the cell membrane architecture, phospholipid disturbances, and mitochondrial targets. This gives ample scope for further investigations toward the rational development of sustainable anti-kinetoplastid drugs.
ORCID iDs
Ebiloma, Godwin U., Ichoron, Nahandoo, Siheri, Weam ORCID: https://orcid.org/0000-0001-6569-7281, Watson, David G. ORCID: https://orcid.org/0000-0003-1094-7604, Igoli, John O. and De Koning, Harry P.;-
-
Item type: Article ID code: 74733 Dates: DateEvent5 November 2020Published3 November 2020AcceptedSubjects: Medicine > Pharmacy and materia medica Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 30 Nov 2020 15:06 Last modified: 05 Sep 2024 22:34 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/74733